George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
You can't delete message on here, the only thing that can happen is LSE removes them
I would have to disagree with that as MODE knew what they were doing when dropping the bitcoin jar, if they didn't drop it then the FCA would not have given MODE the licences. I was just correcting you on the rubbish you keep spouting. Everything you have said to try and bash MODE is just lies. When did I ever say your comments affected the share price, your not that important
New_Dawn why are you still here then if you gave up at 40p. Not everybody is as weak and will hold out for the good days
I've not given up. I continue to add shares as I know why I invested in MODE to start woth and nothing has changed other then the price. I was happy to buy in at 50p and over the moon to buy at 11p, thanks for the discount Mr Rowland. MODE will become good. If you have done your research you will also know why you invested. Stay strong
If Ryan moore was selling he would have sold by now, in which case the market would have to be informed by r.n.s. You have also forgot about the money MODE have from the bitcoin they just sold, no need for a placing.
Colsole how can you blame JR? he has just taken over, give the guy a chance. You know why you invested, so why sell? Not much has changed for the bad. I don't want the price down here but would i sell my holding, no. All i will do is top up / average down as i know why i invested here and believe in MODE & JR
No this will not go much further down as if you add all the cash & value of 2 x licence it come to around the current market cap. Once the 1st piece of good news lands these will move quickly. We also now know that 1 of the 3 infamous companies have also signed up along with bigger companies
Bigbadbob you lost money as you've sold, get Iver it and move on.... as for me, I didn't sell and have been buying plenty more at a bargain price thanks to the weak people that sold.
RNS Number : 8100A
Mode Global Holdings PLC
07 February 2022
Mode Global Holdings PLC
("Mode" or "the Company" or "the Group")
Mode announces Bitcoin payroll partnership with ecommerce firm Heroes
? Deal with ecommerce firm Heroes will allow employees to take salary in Bitcoin
? Mode's innovative payroll platform will deliver Bitcoin to employees' wallets
? Heroes to be one of the first companies in UK to be offering to pay its employees in Bitcoin
Mode Global Holdings PLC (LSE:MODE), the LSE-listed Fintech Group, today announces it has entered into a partnership with technology-driven ecommerce platform Heroes, which will enable employees of the firm to take some of their monthly salary in Bitcoin.
Mode's payroll offering allows interested employees the option to invest in the crypto asset on a monthly basis, which means they can ride the monthly fluctuations in price and invest steadily in the world's most popular digital asset.
As an innovative and fast-growing business which has recently undergone a series of successful fund raises and is backed by 360 Capital Partners, Fuel Ventures and Upper90, Heroes is looking to use Mode's platform as an additional benefit for its employees.
Once employees make the decision to receive a portion of their salary in Bitcoin, they will receive their Bitcoin salary straight into their Mode wallet, which is a secure and FCA registered Bitcoin wallet.
The move highlights the expanding #PayMeInBitcoin movement and follows the partnership between Mode and payroll supplier PayEscape in November 2021.
Recent research of Bitcoin investors commissioned by Mode showed that 76% of UK respondents would be interested in an automated Bitcoin investment when receiving their salary, increasing to 81% of 25-34 year olds.[1]
Commenting on the partnership, Rita Liu, CCO at Mode, said: "We are delighted to be working with the Heroes team to bring their employees an innovative and secure way of investing in Bitcoin for the longer term through our payroll product. They are a great example of forward-thinking employers who answer to increasing demand from the employees' community to be paid in digital assets."
Giancarlo Bruni, Co-founder and CFO at Heroes, said: "We are very excited about the partnership with Mode, which through their Bitcoin payroll platform allows us to offer something very unique and innovative to our employees. Being able to receive salaries partly in Bitcoin has been very well received and adds another string to the bow of benefits available to our employees."
ENDS
Bridgedogg1 - "no evidence just me own assumption" and your assumption would be very wrong. Stop with this crap that Ryan is selling, your just spreding lies
Yes agreed, Ryan is not selling. People will still hang on to the idea that he might be selling although we know he isn't.
Could of been a number of reasons why he left. Yes it could be bad, it could of been a family reason or something else. One thing we know is Ryan isn't selling any shares. We finished today in blue so could actually be the turn around we have been waiting for. Personally I believe in MODE and will continue to add and hold for years to come
What makes you think that then?
You all seem so confident that its Ryan selling. Personally I don't think it is, for all you know its Johnathan selling up. To be fair I don't really care who is selling, I belive in MODE and it will become good, if that takes 6months then that's 6 months of top ups for me :-D
100% The Queen is buying
The closing price was 2.35 so would have a guess at thats a sell not a buy
No i didn't get a notification from VOX this morning either
Why would MODE go down after THG had a bad day? MODE is only a payment provider.
A few director buys have gone few in the last 24 hours. Not massive amounts but it's a start. Why would they waste any money if they knew MODE was a dud. MODE will become very good once all the systems are up and running with The Hut Group and any other companies they get on board.
MGC Pharmaceuticals Ltd.
Notification of ASX Market Announcements
20 September 2021
ASX, LSE: MXC
MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') advises that the following Announcements were released on the ASX Market Announcements Platform today.
· Appendix 2A - Application for quotation of 17,923,153 Fully Paid Ordinary Shares issued as deferred purchase consideration in relation to the acquisition of MediCaNL Inc in April 2021 (Refer ASX announcement dated 22 April 2021).
A copy of the ASX Announcement (Appendix 2A) can be found at the following URL:
https://wcsecure.weblink.com.au/pdf/MXC/02423626.pdf
· Appendix 2A - Application for quotation of 300,000 Fully Paid Ordinary Shares issued on the exercise of 300,000 Employee Performance Rights
A copy of the ASX Announcement can be found at the following URL:
https://wcsecure.weblink.com.au/pdf/MXC/02423628.pdf
· Issue of a "Cleansing Notice" required under s708A(5)(e) of the Australian Corporations Act 2001 (Cth) in relation to the issue of the above shares.
A copy of the ASX Announcement can be found at the following URL:
https://wcsecure.weblink.com.au/pdf/MXC/02423633.pdf
--Ends--
Authorised for release by the Executive Chairman, for further information please contact:
MGC Pharmaceuticals Ltd
Roby Zomer
CEO & Managing Director
+61 8 6382 3390
info@mgcpharma.com.au
MGC Pharmaceuticals Ltd
David Lim
Company Secretary
+61 8 6382 3390
info@mgcpharma.com.au
UK Broker - Turner Pope
Andy Thacker
+44 203 657 0050
info@turnerpope.com
UK PR Advisors - Tavistock
Charles Vivian / Tim Pearson
+44 207 920 3150
mgcpharma@tavistock.co.uk
About MGC Pharma
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - epilepsy and dementia - and has further products in the development pipeline.
Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.
MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeu